NASDAQ : TYRA
Tyra Biosciences, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 21.07 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.45B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 34.14M | 29.83M | 24.10M | 17.43M | 15.92M | 5.65M |
| Research & Development | 126.32M | 102.93M | 80.08M | 62.52M | 43.01M | 20.64M |
| Operating Expenses | 160.46M | 132.76M | 104.18M | 79.94M | 58.93M | 26.29M |
| Operating Income | -160.46M | -132.76M | -104.18M | -79.94M | -58.93M | -26.29M |
| Interest & Investment Income | 11.90M | 12.81M | 17.70M | 10.81M | 3.65M | 13.00K |
| Other Non Operating Income (Expenses) | -50.00K | -19.00K | ||||
| Pretax Income | -148.56M | -119.95M | -86.48M | -69.13M | -55.33M | -26.29M |
| Net Income | -148.56M | -119.95M | -86.48M | -69.13M | -55.33M | -26.29M |
| Net Income to Common | -148.56M | -119.95M | -86.48M | -69.13M | -55.33M | -26.29M |
| Shares Outstanding (Basic) | 61.82M | 59.60M | 57.22M | 42.70M | 41.88M | 13.78M |
| Shares Outstanding (Diluted) | 61.82M | 59.60M | 57.22M | 42.70M | 41.88M | 13.78M |
| EPS (Basic) | -2.40 | -2.01 | -1.51 | -1.62 | -1.32 | -1.91 |
| EPS (Diluted) | -2.40 | -2.01 | -1.51 | -1.62 | -1.32 | -1.91 |
| Free Cash Flow | -109.90M | -95.28M | -70.44M | -50.91M | -50.84M | -24.41M |
| Free Cash Flow Per Share | -1.78 | -1.60 | -1.23 | -1.19 | -1.21 | -1.77 |
| EBITDA | -159.92M | -132.22M | -103.66M | -79.59M | -58.63M | -26.15M |
| D&A For EBITDA | 539.00K | 546.00K | 519.00K | 357.00K | 296.00K | 140.00K |
| EBIT | -160.46M | -132.76M | -104.18M | -79.94M | -58.93M | -26.29M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 73.83M | 77.39M | 91.97M | 58.01M | 251.21M | 302.18M |
| Short-Term Investments | 280.11M | 178.62M | 249.47M | 145.46M | ||
| Cash & Short-Term Investments | 353.94M | 256.00M | 341.44M | 203.47M | 251.21M | 302.18M |
| Other Receivables | 2.50M | 1.90M | 2.00M | 700.00K | ||
| Receivables | 2.50M | 1.90M | 2.00M | 700.00K | ||
| Prepaid Expenses | 10.41M | 7.55M | 4.02M | 7.50M | 6.08M | 1.88M |
| Total Current Assets | 366.97M | 265.45M | 347.46M | 211.67M | 257.29M | 304.06M |
| Property, Plant & Equipment | 6.48M | 6.89M | 7.72M | 8.15M | 3.54M | 2.09M |
| Other Long-Term Assets | 9.91M | 10.27M | 8.38M | 6.03M | 5.35M | 555.00K |
| Total Assets | 383.36M | 282.61M | 363.56M | 225.86M | 266.18M | 306.70M |
| Accounts Payable | 2.33M | 1.18M | 590.00K | 4.66M | 1.15M | 552.00K |
| Accrued Expenses | 21.78M | 16.44M | 13.59M | 10.39M | 4.42M | 2.86M |
| Current Portion of Leases | 504.00K | 472.00K | 412.00K | 280.00K | 140.00K | 202.00K |
| Total Current Liabilities | 24.62M | 18.09M | 14.59M | 15.33M | 5.70M | 3.62M |
| Long-Term Leases | 5.08M | 5.34M | 5.81M | 6.22M | 2.48M | 981.00K |
| Other Long-Term Liabilities | 3.00K | 46.00K | 169.00K | 367.00K | ||
| Total Liabilities | 29.70M | 23.43M | 20.41M | 21.59M | 8.35M | 4.96M |
| Common Stock | 6.00K | 5.00K | 5.00K | 4.00K | 4.00K | 4.00K |
| Additional Paid-In Capital | 810.36M | 630.04M | 593.69M | 368.71M | 353.52M | 342.10M |
| Retained Earnings | -456.12M | -371.26M | -251.31M | -164.83M | -95.70M | -40.37M |
| Comprehensive Income & Other | -580.00K | 393.00K | 770.00K | 381.00K | ||
| Total Common Equity | 353.66M | 259.18M | 343.15M | 204.26M | 257.83M | 301.74M |
| Shareholders' Equity | 353.66M | 259.18M | 343.15M | 204.26M | 257.83M | 301.74M |
| Total Liabilities & Equity | 383.36M | 282.61M | 363.56M | 225.86M | 266.18M | 306.70M |
| Total Debt | 5.58M | 5.81M | 6.22M | 6.50M | 2.62M | 1.18M |
| Net Cash (Debt) | 348.36M | 250.19M | 335.22M | 196.97M | 248.59M | 301.00M |
| Net Cash Per Share | 5.63 | 4.20 | 5.86 | 4.61 | 5.94 | 21.84 |
| Filing Date Shares Outstanding | 59.68M | 53.87M | 53.09M | 52.52M | 42.43M | 41.11M |
| Total Common Shares Outstanding | 59.66M | 53.71M | 50.75M | 43.02M | 42.35M | 40.95M |
| Working Capital | 342.35M | 247.36M | 332.87M | 196.34M | 251.59M | 300.44M |
| Book Value Per Share | 5.93 | 4.83 | 6.76 | 4.75 | 6.09 | 7.37 |
| Tangible Book Value | 353.66M | 259.18M | 343.15M | 204.26M | 257.83M | 301.74M |
| Tangible Book Value Per Share | 5.93 | 4.83 | 6.76 | 4.75 | 6.09 | 7.37 |
| Machinery | 2.03M | 1.38M | 1.05M | |||
| Leasehold Improvements | 402.00K | 156.00K | 141.00K |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -148.56M | -119.95M | -86.48M | -69.13M | -55.33M | -26.29M |
| Depreciation & Amortization | 539.00K | 546.00K | 519.00K | 357.00K | 296.00K | 140.00K |
| Loss (Gain) From Sale of Assets | 3.00K | 3.00K | ||||
| Loss (Gain) From Sale of Investments | -775.00K | -2.12M | -5.88M | -1.25M | ||
| Stock-Based Compensation | 33.28M | 28.01M | 22.80M | 13.53M | 10.59M | 2.89M |
| Change in Accounts Payable | 10.74M | 3.37M | -744.00K | 9.37M | 2.36M | 1.49M |
| Change in Other Net Operating Assets | -4.87M | -5.00M | 15.00K | -3.01M | -8.20M | -1.97M |
| Operating Cash Flow | -109.65M | -95.14M | -69.77M | -50.14M | -50.28M | -23.75M |
| Capital Expenditures | -250.00K | -141.00K | -664.00K | -770.00K | -559.00K | -661.00K |
| Sale of Property, Plant & Equipment | 16.00K | |||||
| Investment in Securities | -82.57M | 72.60M | -97.74M | -143.84M | ||
| Investing Cash Flow | -82.82M | 72.46M | -98.40M | -144.60M | -559.00K | -645.00K |
| Long-Term Debt Repaid | -9.00K | |||||
| Net Debt Issued (Repaid) | -9.00K | |||||
| Issuance of Common Stock | 169.91M | 8.10M | 202.56M | 1.54M | 632.00K | 181.73M |
| Other Financing Activities | -2.10M | -420.00K | ||||
| Financing Cash Flow | 167.81M | 8.10M | 202.14M | 1.54M | 632.00K | 311.35M |
| Net Cash Flow | -24.66M | -14.58M | 33.96M | -193.21M | -50.21M | 286.96M |
| Free Cash Flow | -109.90M | -95.28M | -70.44M | -50.91M | -50.84M | -24.41M |
| Free Cash Flow Per Share | -1.78 | -1.60 | -1.23 | -1.19 | -1.21 | -1.77 |
| Levered Free Cash Flow | -63.07M | -54.55M | -41.15M | -29.49M | -28.56M | -14.18M |
| Unlevered Free Cash Flow | -63.07M | -54.55M | -41.15M | -29.49M | -28.56M | -14.18M |
| Cash Interest Paid | 1.24M | |||||
| Change in Working Capital | 5.87M | -1.63M | -729.00K | 6.36M | -5.85M | -481.00K |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 1.45B | 1.40B | 731.18M | 596.34M | 317.87M | 571.90M |
| Enterprise Value | 1.10B | 1.13B | 377.37M | 386.80M | 57.30M | 260.25M |
| Last Close Price | 21.07 | 26.29 | 13.90 | 13.85 | 7.60 | 14.07 |
| PB Ratio | 3.55 | 5.41 | 2.13 | 2.92 | 1.23 | 1.90 |
| P/TBV Ratio | 4.10 | 5.41 | 2.13 | 2.92 | 1.23 | 1.90 |
| Debt / Equity Ratio | 0.02 | 0.02 | 0.02 | 0.03 | 0.01 | 0.00 |
| Net Debt / Equity Ratio | -0.98 | -0.96 | -0.98 | -0.96 | -0.96 | -1.00 |
| Net Debt / EBITDA Ratio | 2.18 | 1.89 | 3.23 | 2.48 | 4.24 | 11.51 |
| Net Debt / FCF Ratio | 3.17 | 2.63 | 4.76 | 3.87 | 4.89 | 12.33 |
| Quick Ratio | 14.48 | 14.25 | 23.53 | 13.32 | 44.06 | 83.57 |
| Current Ratio | 14.90 | 14.67 | 23.81 | 13.80 | 45.13 | 84.09 |
| Return on Equity (ROE) | -45.31% | -39.83% | -31.60% | -29.92% | -19.77% | -16.66% |
| Return on Assets (ROA) | -28.46% | -25.68% | -22.09% | -20.31% | -12.86% | -10.18% |
| Return on Capital Employed (ROCE) | -44.70% | -50.20% | -29.90% | -38.00% | -22.60% | -8.70% |
| Earnings Yield | -11.41% | -8.55% | -11.83% | -11.59% | -17.41% | -4.60% |
| FCF Yield | -7.59% | -6.79% | -9.63% | -8.54% | -16.00% | -4.27% |
| Buyback Yield / Dilution | -4.40% | -4.17% | -33.98% | -1.96% | -203.94% | -793.58% |